Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Current Liabilities: 2021-2024

Historic Total Current Liabilities for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $23.4 million.

  • ARS Pharmaceuticals' Total Current Liabilities rose 206.06% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 206.06%. This contributed to the annual value of $23.4 million for FY2024, which is 880.34% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Total Current Liabilities of $23.4 million as of FY2024, which was up 880.34% from $2.4 million recorded in FY2023.
  • ARS Pharmaceuticals' Total Current Liabilities' 5-year high stood at $23.4 million during FY2024, with a 5-year trough of $2.4 million in FY2023.
  • In the last 3 years, ARS Pharmaceuticals' Total Current Liabilities had a median value of $5.4 million in 2022 and averaged $10.4 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 56.08% in 2023, then surged by 880.34% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Total Current Liabilities (Yearly) stood at $8.2 million in 2021, then tumbled by 33.50% to $5.4 million in 2022, then tumbled by 56.08% to $2.4 million in 2023, then surged by 880.34% to $23.4 million in 2024.